The authors performed a randomized control study of 178 patients with heart failure and systolic dyssynchrony who were accepted for CABG, randomizing the participants into two groups: CABG alone (n=87) and CABG + concomitant epicardial CRT (n=91). CRT was activated postoperatively. At a mean follow-up period of 55 months, the mortality rate of the CABG group was 36% and that of the CABG + CRT group was 15%. Moreover, all-cause mortality, cardiac death, and hospital readmissions were significantly lower for the CABG + CRT group.
It is known that not all patients with potential indications for CRT undergoing CABG will meet the criteria for CRT postoperatively. The question is whether performing CRT at the time of CABG in all such patients is a cost-effective strategy.
You are here:
Cardiac resynchronization therapy combined with coronary artery bypass grafting in ischaemic heart failure patients: long-term results of the RESCUE study
Submitted by: Arie Blitz
Source: European Journal of Cardio-Thoracic Surgery
Keywords:
Author(s): Alexander Romanova,*, Kinga Goscinska-Bisb, Jaroslaw Bisb, Alexander Chernyavskiya, Darya Prokhorovaa, Yana Syrtsevaa, Vitaliy Shabanova, Sergey Alsova, Alexander Karaskova, Marek Dejab, Michal Krejcab and Evgeny Pokushalova
3 Comments
This is a remarkable result with almost 50% mortality reduction. I would predict that cost effectiveness will, most likely be in the positive if one consider post-operative length of stay inclusive cost of potential inotropic drugs and other potential support devices to sustain good hemodynamic performance. In any case, I shall congratulate the authors & encourage others to join the investigation.
This is a remarkable result with almost 50% mortality reduction. I would predict that cost effectiveness will, most likely, be in the positive if one consider post-operative length of stay inclusive cost of potential inotropic drugs and other potential support devices to sustain good hemodynamic performance. In any case, I shall congratulate the authors & encourage others to join the investigation.
This is a remarkable result with almost 50% mortality reduction. I would predict that cost effectiveness will, most likely, be in the positive side if one consider post-operative length of stay inclusive cost of potential inotropic drugs and other potential support devices to sustain good hemodynamic performance. In any case, I shall congratulate the authors & encourage others to join the investigation.